CA2816388C - Maintaining multiple defined physiological zones using model predictive control - Google Patents

Maintaining multiple defined physiological zones using model predictive control Download PDF

Info

Publication number
CA2816388C
CA2816388C CA2816388A CA2816388A CA2816388C CA 2816388 C CA2816388 C CA 2816388C CA 2816388 A CA2816388 A CA 2816388A CA 2816388 A CA2816388 A CA 2816388A CA 2816388 C CA2816388 C CA 2816388C
Authority
CA
Canada
Prior art keywords
zone
insulin
controller
control
zones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2816388A
Other languages
English (en)
French (fr)
Other versions
CA2816388A1 (en
Inventor
Francis J. Doyle, Iii
Benyamin Grosman
Eyal Dassau
Lois Jovanovic
Howard Zisser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANSUM DIABETES RESEARCH INSTITUTE
University of California San Diego UCSD
Original Assignee
SANSUM DIABETES RESEARCH INSTITUTE
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SANSUM DIABETES RESEARCH INSTITUTE, University of California San Diego UCSD filed Critical SANSUM DIABETES RESEARCH INSTITUTE
Publication of CA2816388A1 publication Critical patent/CA2816388A1/en
Application granted granted Critical
Publication of CA2816388C publication Critical patent/CA2816388C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
CA2816388A 2010-10-12 2011-10-12 Maintaining multiple defined physiological zones using model predictive control Active CA2816388C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39239910P 2010-10-12 2010-10-12
US61/392,399 2010-10-12
PCT/US2011/056022 WO2012051344A2 (en) 2010-10-12 2011-10-12 Maintaining multiple defined physiological zones using model predictive control

Publications (2)

Publication Number Publication Date
CA2816388A1 CA2816388A1 (en) 2012-04-19
CA2816388C true CA2816388C (en) 2016-12-06

Family

ID=45938960

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2816388A Active CA2816388C (en) 2010-10-12 2011-10-12 Maintaining multiple defined physiological zones using model predictive control

Country Status (7)

Country Link
US (1) US9700708B2 (https=)
EP (1) EP2628115B1 (https=)
JP (1) JP6062859B2 (https=)
CA (1) CA2816388C (https=)
DK (1) DK2628115T3 (https=)
ES (1) ES2544874T3 (https=)
WO (1) WO2012051344A2 (https=)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8417311B2 (en) 2008-09-12 2013-04-09 Optiscan Biomedical Corporation Fluid component analysis system and method for glucose monitoring and control
WO2009049252A1 (en) 2007-10-10 2009-04-16 Optiscan Biomedical Corporation Fluid component analysis system and method for glucose monitoring and control
US7959598B2 (en) 2008-08-20 2011-06-14 Asante Solutions, Inc. Infusion pump systems and methods
US9757510B2 (en) 2012-06-29 2017-09-12 Animas Corporation Method and system to handle manual boluses or meal events for closed-loop controllers
US9486578B2 (en) * 2012-12-07 2016-11-08 Animas Corporation Method and system for tuning a closed-loop controller for an artificial pancreas
US9907909B2 (en) * 2012-12-20 2018-03-06 Animas Corporation Method and system for a hybrid control-to-target and control-to-range model predictive control of an artificial pancreas
KR102212020B1 (ko) * 2013-01-14 2021-02-05 더 리전트 오브 더 유니버시티 오브 캘리포니아 제1형 당뇨병 응용을 위한 인공 췌장에 대한 모델 예측 제어 문제에서의 일주기 목표-구역 조절
EP2973095B1 (en) 2013-03-15 2018-05-09 Animas Corporation Insulin time-action model
US9795737B2 (en) 2013-03-15 2017-10-24 Animas Corporation Method and system for closed-loop control of an artificial pancreas
US9517306B2 (en) 2013-03-15 2016-12-13 Animas Corporation Method and system for closed-loop control of an artificial pancreas
US9561324B2 (en) 2013-07-19 2017-02-07 Bigfoot Biomedical, Inc. Infusion pump system and method
US9474855B2 (en) 2013-10-04 2016-10-25 Animas Corporation Method and system for controlling a tuning factor due to sensor replacement for closed-loop controller in an artificial pancreas
US9861747B2 (en) 2013-12-05 2018-01-09 Lifescan, Inc. Method and system for management of diabetes with a glucose monitor and infusion pump to provide feedback on bolus dosing
GB2523989B (en) 2014-01-30 2020-07-29 Insulet Netherlands B V Therapeutic product delivery system and method of pairing
AU2015301146B2 (en) 2014-08-06 2020-06-25 Regents Of The University Of California Moving-horizon state-initializer for control applications
CN111905188B (zh) 2015-02-18 2022-07-22 英赛罗公司 流体输送和输注装置及其使用方法
US10275573B2 (en) 2016-01-13 2019-04-30 Bigfoot Biomedical, Inc. User interface for diabetes management system
US10806859B2 (en) 2016-01-14 2020-10-20 Bigfoot Biomedical, Inc. Adjusting insulin delivery rates
HK1256995A1 (zh) 2016-01-14 2019-10-11 Bigfoot Biomedical, Inc. 药物输送设备、系统和方法中的阻塞解决方案
FR3047098B1 (fr) * 2016-01-21 2018-05-25 Voluntis Gestion de l'equilibre glycemique d'un patient diabetique
RU2737326C2 (ru) * 2016-02-05 2020-11-27 Энимас Корпорейшн Средство наглядного представления и анализа для системы доставки лекарственных средств
US12383166B2 (en) 2016-05-23 2025-08-12 Insulet Corporation Insulin delivery system and methods with risk-based set points
WO2018058041A1 (en) 2016-09-23 2018-03-29 Insulet Corporation Fluid delivery device with sensor
CA3037432A1 (en) 2016-12-12 2018-06-21 Bigfoot Biomedical, Inc. Alarms and alerts for medication delivery devices and related systems and methods
US10583250B2 (en) 2017-01-13 2020-03-10 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
US10758675B2 (en) 2017-01-13 2020-09-01 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
US10881793B2 (en) 2017-01-13 2021-01-05 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
EP3568860B1 (en) 2017-01-13 2025-12-10 Insulet Corporation Insulin delivery methods, systems and devices
US10500334B2 (en) 2017-01-13 2019-12-10 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
EP4708311A2 (en) 2017-01-13 2026-03-11 Insulet Corporation Insulin delivery methods, systems and devices
US11497851B2 (en) 2017-03-31 2022-11-15 Lifescan Ip Holdings, Llc Maintaining maximum dosing limits for closed loop insulin management systems
US10729849B2 (en) 2017-04-07 2020-08-04 LifeSpan IP Holdings, LLC Insulin-on-board accounting in an artificial pancreas system
US11147920B2 (en) 2017-04-18 2021-10-19 Lifescan Ip Holdings, Llc Diabetes management system with automatic basal and manual bolus insulin control
CA3198598A1 (en) 2017-05-05 2018-11-08 Eli Lilly And Company Closed loop control of physiological glucose
EP3438858A1 (en) 2017-08-02 2019-02-06 Diabeloop Closed-loop blood glucose control systems and methods
WO2019125932A1 (en) 2017-12-21 2019-06-27 Eli Lilly And Company Closed loop control of physiological glucose
JP6938363B2 (ja) * 2017-12-27 2021-09-22 オムロンヘルスケア株式会社 情報処理装置、生体情報測定装置、方法及びプログラム
USD928199S1 (en) 2018-04-02 2021-08-17 Bigfoot Biomedical, Inc. Medication delivery device with icons
US11147919B2 (en) 2018-04-23 2021-10-19 Medtronic Minimed, Inc. Methodology to recommend and implement adjustments to a fluid infusion device of a medication delivery system
US11158413B2 (en) * 2018-04-23 2021-10-26 Medtronic Minimed, Inc. Personalized closed loop medication delivery system that utilizes a digital twin of the patient
EP3788628B1 (en) 2018-05-04 2024-12-11 Insulet Corporation Safety constraints for a control algorithm-based drug delivery system
US12562251B1 (en) 2018-05-09 2026-02-24 Bigfoot Biomedical, Inc. Computing architecture for assuring the provenance of medication therapy related parameters, and related systems, methods and devices
CN112313754A (zh) 2018-06-22 2021-02-02 伊莱利利公司 胰岛素和普兰林肽输送系统、方法和设备
US11628251B2 (en) 2018-09-28 2023-04-18 Insulet Corporation Activity mode for artificial pancreas system
EP3864668A1 (en) 2018-10-11 2021-08-18 Insulet Corporation Event detection for drug delivery system
USD920343S1 (en) 2019-01-09 2021-05-25 Bigfoot Biomedical, Inc. Display screen or portion thereof with graphical user interface associated with insulin delivery
US11986629B2 (en) 2019-06-11 2024-05-21 Medtronic Minimed, Inc. Personalized closed loop optimization systems and methods
US11801344B2 (en) 2019-09-13 2023-10-31 Insulet Corporation Blood glucose rate of change modulation of meal and correction insulin bolus quantity
US11935637B2 (en) 2019-09-27 2024-03-19 Insulet Corporation Onboarding and total daily insulin adaptivity
WO2021113647A1 (en) 2019-12-06 2021-06-10 Insulet Corporation Techniques and devices providing adaptivity and personalization in diabetes treatment
US11833329B2 (en) 2019-12-20 2023-12-05 Insulet Corporation Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns
JP7512395B2 (ja) 2020-01-06 2024-07-08 インスレット コーポレイション 持続する残差に基づく食事および／または運動行為の予測
US12370307B2 (en) 2020-02-03 2025-07-29 Insulet Corporation Use of fuzzy logic in predicting user behavior affecting blood glucose concentration in a closed loop control system of an automated insulin delivery device
US11551802B2 (en) 2020-02-11 2023-01-10 Insulet Corporation Early meal detection and calorie intake detection
US11547800B2 (en) 2020-02-12 2023-01-10 Insulet Corporation User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system
US11986630B2 (en) 2020-02-12 2024-05-21 Insulet Corporation Dual hormone delivery system for reducing impending hypoglycemia and/or hyperglycemia risk
US11324889B2 (en) 2020-02-14 2022-05-10 Insulet Corporation Compensation for missing readings from a glucose monitor in an automated insulin delivery system
US12495994B2 (en) 2020-02-20 2025-12-16 Insulet Corporation Meal bolus subcategories in model based insulin therapy
US11607493B2 (en) 2020-04-06 2023-03-21 Insulet Corporation Initial total daily insulin setting for user onboarding
WO2022020197A1 (en) 2020-07-22 2022-01-27 Insulet Corporation Open-loop insulin delivery basal parameters based on insulin delivery records
US11684716B2 (en) 2020-07-31 2023-06-27 Insulet Corporation Techniques to reduce risk of occlusions in drug delivery systems
US12569619B2 (en) 2020-09-21 2026-03-10 Insulet Corporation Techniques for determining automated insulin delivery dosages
EP4221588A1 (en) 2020-09-30 2023-08-09 Insulet Corporation Secure wireless communications between a glucose monitor and other devices
WO2022072332A1 (en) 2020-09-30 2022-04-07 Insulet Corporation Drug delivery device with integrated optical-based glucose monitor
US11160925B1 (en) 2021-01-29 2021-11-02 Insulet Corporation Automatic drug delivery system for delivery of a GLP-1 therapeutic
US11904140B2 (en) 2021-03-10 2024-02-20 Insulet Corporation Adaptable asymmetric medicament cost component in a control system for medicament delivery
EP4305636A1 (en) 2021-03-10 2024-01-17 Insulet Corporation A medicament delivery device with an adjustable and piecewise analyte level cost component to address persistent positive analyte level excursions
US12592306B2 (en) 2021-04-28 2026-03-31 Insulet Corporation Devices and methods for initialization of drug delivery devices using measured analyte sensor information
US12496398B2 (en) 2021-05-28 2025-12-16 Insulet Corporation Threshold based automatic glucose control response
US12406760B2 (en) 2021-06-07 2025-09-02 Insulet Corporation Exercise safety prediction based on physiological conditions
US12514980B2 (en) 2021-06-30 2026-01-06 Insulet Corporation Adjustment of medicament delivery by a medicament delivery device based on menstrual cycle phase
US12521486B2 (en) 2021-07-16 2026-01-13 Insulet Corporation Method for modification of insulin delivery during pregnancy in automatic insulin delivery systems
WO2023049900A1 (en) 2021-09-27 2023-03-30 Insulet Corporation Techniques enabling adaptation of parameters in aid systems by user input
US11439754B1 (en) 2021-12-01 2022-09-13 Insulet Corporation Optimizing embedded formulations for drug delivery
EP4243030A1 (en) 2022-03-09 2023-09-13 Insulet Corporation Adjusting medicament delivery parameters in an open loop medicament delivery mode
CN120457493A (zh) 2023-01-06 2025-08-08 英赛罗公司 自动或手动启动的随餐推注输送及随后的自动安全约束放宽
US20250166810A1 (en) * 2023-11-22 2025-05-22 Cilag Gmbh International Data streams multi-system interaction

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3251224B2 (ja) * 1998-02-26 2002-01-28 勲 長澤 病棟情報システム
US8423113B2 (en) * 2003-07-25 2013-04-16 Dexcom, Inc. Systems and methods for processing sensor data
US8369919B2 (en) * 2003-08-01 2013-02-05 Dexcom, Inc. Systems and methods for processing sensor data
US9135402B2 (en) * 2007-12-17 2015-09-15 Dexcom, Inc. Systems and methods for processing sensor data
WO2006124716A2 (en) * 2005-05-13 2006-11-23 Trustees Of Boston University Fully automated control system for type 1 diabetes
US9392969B2 (en) * 2008-08-31 2016-07-19 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
WO2008057384A2 (en) * 2006-11-02 2008-05-15 The University Of North Carolina At Chapel Hill Methods and systems for determining an intravenous insulin infusion rate
US20080154513A1 (en) * 2006-12-21 2008-06-26 University Of Virginia Patent Foundation Systems, Methods and Computer Program Codes for Recognition of Patterns of Hyperglycemia and Hypoglycemia, Increased Glucose Variability, and Ineffective Self-Monitoring in Diabetes
EP2139540A1 (en) * 2007-03-19 2010-01-06 Medingo Ltd. User interface for selecting bolus doses in a drug delivery device
US8221345B2 (en) * 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
WO2009139846A1 (en) * 2008-05-12 2009-11-19 Department Of Veterans Affairs Automated system and method for diabetes control
CA2753650A1 (en) * 2008-11-26 2010-06-03 University Of Virginia Patent Foundation Method, system, and computer program product for tracking of blood glucose variability in diabetes
US8562587B2 (en) * 2009-02-25 2013-10-22 University Of Virginia Patent Foundation CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction of insulin delivery

Also Published As

Publication number Publication date
JP2013542011A (ja) 2013-11-21
WO2012051344A2 (en) 2012-04-19
JP6062859B2 (ja) 2017-01-18
EP2628115B1 (en) 2015-06-03
HK1182496A1 (en) 2013-11-29
US20130231642A1 (en) 2013-09-05
DK2628115T3 (en) 2015-08-24
EP2628115A4 (en) 2014-04-23
ES2544874T3 (es) 2015-09-04
CA2816388A1 (en) 2012-04-19
US9700708B2 (en) 2017-07-11
EP2628115A2 (en) 2013-08-21
WO2012051344A3 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
CA2816388C (en) Maintaining multiple defined physiological zones using model predictive control
EP2967450B1 (en) System for closed-loop control of an artificial pancreas
EP2521483B1 (en) System to deliver insulin to a subject
JP7153668B2 (ja) 自動基礎インスリン制御及び手動ボーラスインスリン制御を有する糖尿病管理システム
Cobelli et al. Artificial pancreas: past, present, future
JP7278216B2 (ja) 遡及的な仮想基礎レートを用いて、インスリン送達を制御するための方法およびシステム
CN104394907B (zh) 在闭环控制器中处理手动推注或膳食事件的方法和系统
TWI671094B (zh) 用於控制人工胰臟中之封閉迴路控制器因感測器更換後之調諧因子的系統
US9907909B2 (en) Method and system for a hybrid control-to-target and control-to-range model predictive control of an artificial pancreas
AU2013355206B2 (en) Method and system for tuning a closed-loop controller for an artificial pancreas
EP3785276A1 (en) Personalized closed loop medication delivery system that utilizes a digital twin of the patient
US20080097289A1 (en) Intelligent Therapy Recommendation Algorithm and Method of Using the Same
WO2017123805A1 (en) Predictive control model for the artificial pancreas using past predictions
Messori et al. Artificial pancreas: from in-silico to in-vivo
CN110352460A (zh) 人工胰腺
HK1182496B (en) Insulin delivery device
Prud'Homme et al. Preclinically assessed optimal control of postprandial glucose excursions for type 1 patients with diabetes
El Hachimi et al. Overcoming control challenges in the artificial pancreas
Stemmann et al. Diabetic Blood Glucose Control via Optimization over Insulin and Glucose Doses

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130405

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240923

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240923